Epidemiological studies suggest that women with heart failure differ from m
en with heart failure in that their survival is better. Therapeutic trials
have not clearly demonstrated a survival benefit for women. This study was
to determine the tolerance for high doses of angiotensin-converting enzyme
(ACE) inhibitor-nitrates in women versus men and to compare their symptomat
ic response, exercise tolerance, and ventricular functional improvement ove
r 1 year. Eighty-eight sequential patients with heart failure, 54 men and 3
4 women with left ventricular ejection fraction less than or equal to 35%,
were prospectively followed for 1 year. For all patients, ACE inhibitor-nit
rate therapy was intensified. Each patient had three 6-monthly echocardiogr
ams at baseline, at 6 months, and at 1 year, and metabolic stress testing.
Patients were 57.3 +/- 12.3 years old, with New York Heart Association (NYH
A) class severity 2.6 +/- 1.0. Lisinopril dosages were raised from 14 +/- 1
4 mg/day to 57 +/- 26 mg/day, isosorbide mononitrate from 15 +/- 27 mg/day
to 126 +/- 72 mg/day, and carvedilol (n = 34) to 17 +/- 16 mg/day. Women an
d men were epidemiologically comparable, with similar baseline echocardiogr
aphic parameters (left ventricular ejection fraction 19% +/- 7% versus 17%
+/- 6%, respectively). Both tolerated up-titration in medical therapy. Fina
l 12-month ejection fractions were equivalent for women and men at 34% +/-
17% and 34% +/- 13%, respectively, with similar improvements in left ventri
cular diameters. At 1 year, women had higher resting heart rates and remain
ed more symptomatic with lower exercise capacity. However, the relative cha
nges in NYHA status and aerobic capacity were similar for women and men. Th
us, both women and men tolerated uptitrated ACE inhibitor-nitrate medical t
herapy, with comparable reversal of heart failure remodeling. Although wome
n continued to be more symptomatic than men, relative improvements in sympt
omatic status, in execise capacity, and in hospitalization rate were equiva
lent.